• About us
  • Privacy Policy
  • Contact us
Neo Science Hub
ADVERTISEMENT
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
Neo Science Hub
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Bharat Biotech Launches State-of-the-Art Gene Therapy Production Facility at Genome Valley

Raja Aditya by Raja Aditya
2 years ago
in Healthcare & Medicine, Pharmaceutical & Chemical, Science News
0
Bharat Biotech

Bharat Biotech Launches State-of-the-Art Gene Therapy Production Facility at Genome Valley | Neo Science Hub

Bharat Biotech, a leading player in the biopharmaceutical sector, has taken a significant step forward in the realm of advanced therapeutic solutions by inaugurating a cutting-edge Cell & Gene Therapy (CGT) production plant at Genome Valley. This modern facility, sprawling over 50,000 square feet, is poised to support the development of innovative treatments aimed at oncology and rare diseases, positioning Bharat Biotech at the forefront of regenerative and personalized medicine.

Expanding Horizons

The launch indicates a strategic shift for Bharat Biotech, moving beyond its established reputation in vaccine development to embrace the complexities of gene and cell therapies. These advanced treatment modalities are recognized for their intricate nature, requiring specialized expertise in genetic manipulation and advanced manufacturing techniques. The facility is designed to produce high-titer viral vectors—specifically adeno-associated viruses (AAV), lentiviruses, and adenoviruses—which are crucial for the efficacy of many cell and gene therapy applications.

Focus on Targeted Therapies

According to Dr. Krishna Ella, Executive Chairman of Bharat Biotech, the new facility encapsulates the company’s long-term vision of delivering life-saving treatments tailored to address unmet medical needs globally. He highlighted that the centre’s primary focus will include the development of therapies for haematological malignancies and inherited blood disorders. Dr. Raches Ella, Chief Development Officer, emphasized that among the suite of advanced treatments envisioned, the CD19 CAR T Cell Therapy stands out as a groundbreaking approach to treating blood cancers.

Implications for Patients and the Pharma Industry

The establishment of Bharat Biotech’s CGT facility is anticipated to have far-reaching implications for both patients and the pharmaceutical industry at large. By harnessing cutting-edge technology and advanced biological processes, Bharat aims to significantly enhance the availability and accessibility of innovative therapies specifically designed for conditions previously deemed difficult to treat.

The investment in this infrastructure underscores a growing trend within the biopharmaceutical sector focusing on personalized medicine, where treatments are tailored to individual patients’ genetic profiles, improving both efficacy and safety.

As Bharat Biotech advances into this new domain of cell and gene therapy, it reaffirms its commitment to addressing some of the most challenging medical issues of our time. By developing next-generation therapies, the company not only aims to improve treatment outcomes for patients but also aspires to contribute significantly to global health advancements.

-Raja Aditya

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Share on Tumblr (Opens in new window) Tumblr
  • Share on Telegram (Opens in new window) Telegram
  • Email a link to a friend (Opens in new window) Email
Tags: bharat biotechCell & Gene Therapy (CGT)featuredGenome Valleypersonalized medicinerare diseasessciencenews
Raja Aditya

Raja Aditya

Associate Editor for Neo Science Hub Magazine

Other Posts

THE PRICE OF A PAIR OF HANDS

What Does a Humanoid Robot Cost, and When Does It Beat a Wage?

November 22, 2026
0
Dilemma of a Country With More Hands Than Jobs

Humanoid Robots and India: The Dilemma of a Country With More Hands Than Jobs

November 22, 2026
0

If Machines Do the Work, What Is Left for Us?

When the Last Antibiotic Fails: ICMR Finds 91 Per Cent Carbapenem Resistance in a Common Hospital Pathogen

Akvan Turns North and Drops a Category: IMD Now Expects a Severe Cyclone Between Narsapur and Puri, While Andhra’s Own Forecasters Expect Less

Antalya’s Last Forty-Eight Hours: Two Contradictory Paragraphs on Fossil Fuels, and India’s Line on the Carbon Budget

Disarm, Don’t Kill: CCMB Scientists Find Two Compounds That Stop a Deadly Fungus Turning Invasive

Eighty Per Cent of the Cost: Andhra Pradesh Raises the Stakes in India’s Chip-Subsidy Contest

Next Post
Fogging

New Initiative in Hyderabad: GHMC's 'Fogging on Request' to Combat Mosquito Menace

Subscribe to Us

Latest Articles

Cross-section of a human eye with the optic nerve head highlighted

FDA Orders Eye-Risk Warnings on All GLP-1 Drugs, From Ozempic to Mounjaro

November 12, 2026
11

Delhi’s Diwali, Measured: Firecrackers Drove 71% of Fine Particles, Lead Hit 20 Times the Limit, and the Worst Readings Went Missing

Global Carbon Budget 2026: The World’s Fossil Emissions Dip, India’s Rise 4.4%, and the 1.5 °C Budget Is Nearly Spent

A New Kind of Blood Thinner: FDA Approves Asundexian to Prevent Repeat Strokes

Andhra Pradesh Opens the Door to Small Nuclear Reactors, Robots and Giga-Scale AI Data Centres — With the Details Still to Come

“Off the Charts”: WMO Tells COP31 That 2026 Is Among the Hottest Years on Record as a Record El Niño Builds

  • Advertise
  • Terms and Conditions
  • Privacy Policy
  • Refund Policy
  • Contact
For Feedback : Email Us

Copyrights © 2025 Neo Science Hub

No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Copyrights © 2025 Neo Science Hub

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist